Bariatric surgery rates in the US have dropped significantly, with some reports indicating a decline of over 20%. This decrease appears to coincide with a surge in the use of GLP-1 weight loss drugs. The exact relationship between these trends is unclear, but they seem to be related to broader shifts in approaches to weight loss and obesity treatment.